Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Gross Profit (2019 - 2025)

Historic Gross Profit for Coherus Oncology (CHRS) over the last 7 years, with Q3 2025 value amounting to $7.8 million.

  • Coherus Oncology's Gross Profit rose 13623.23% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.4 million, marking a year-over-year increase of 69640.97%. This contributed to the annual value of $149.4 million for FY2024, which is 5206.51% up from last year.
  • Coherus Oncology's Gross Profit amounted to $7.8 million in Q3 2025, which was up 13623.23% from $6.9 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Gross Profit peaked at $136.7 million during Q4 2024, and registered a low of $869000.0 during Q1 2024.
  • Over the past 5 years, Coherus Oncology's median Gross Profit value was $31.2 million (recorded in 2022), while the average stood at $35.6 million.
  • Over the last 5 years, Coherus Oncology's Gross Profit had its largest YoY gain of 186532.99% in 2024, and its largest YoY loss of 9441.59% in 2024.
  • Coherus Oncology's Gross Profit (Quarter) stood at $61.2 million in 2021, then plummeted by 49.14% to $31.2 million in 2022, then plummeted by 77.67% to $7.0 million in 2023, then skyrocketed by 1865.33% to $136.7 million in 2024, then tumbled by 94.26% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q3 2025, $6.9 million for Q2 2025, and $4.9 million during Q1 2025.